Ironwood Pharmaceuticals Net Income 2010-2024 | IRWD

Ironwood Pharmaceuticals net income from 2010 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Ironwood Pharmaceuticals Annual Net Income
(Millions of US $)
2023 $-1,002
2022 $175
2021 $528
2020 $106
2019 $22
2018 $-282
2017 $-117
2016 $-82
2015 $-143
2014 $-190
2013 $-273
2012 $-73
2011 $-65
2010 $-53
2009 $-71
Ironwood Pharmaceuticals Quarterly Net Income
(Millions of US $)
2024-03-31 $-4
2023-12-31 $-1
2023-09-30 $15
2023-06-30 $-1,062
2023-03-31 $46
2022-12-31 $49
2022-09-30 $50
2022-06-30 $37
2022-03-31 $39
2021-12-31 $41
2021-09-30 $56
2021-06-30 $391
2021-03-31 $40
2020-12-31 $43
2020-09-30 $34
2020-06-30 $25
2020-03-31 $3
2019-12-31 $10
2019-09-30 $21
2019-06-30 $12
2019-03-31 $-22
2018-12-31 $-15
2018-09-30 $-174
2018-06-30 $-49
2018-03-31 $-43
2017-12-31 $12
2017-09-30 $-32
2017-06-30 $-44
2017-03-31 $-53
2016-12-31 $-14
2016-09-30 $-33
2016-06-30 $-22
2016-03-31 $-13
2015-12-31 $-14
2015-09-30 $-47
2015-06-30 $-48
2015-03-31 $-33
2014-12-31 $-38
2014-09-30 $-42
2014-06-30 $-60
2014-03-31 $-50
2013-12-31 $-52
2013-09-30 $-62
2013-06-30 $-65
2013-03-31 $-94
2012-12-31 $-44
2012-09-30 $48
2012-06-30 $-41
2012-03-31 $-36
2011-12-31 $-7
2011-09-30 $-21
2011-06-30 $-19
2011-03-31 $-18
2010-12-31 $-12
2010-09-30 $-8
2010-06-30 $-17
2010-03-31 $-16
2009-12-31 $-24
2009-09-30 $-11
2009-06-30 $-18
2009-03-31 $-18
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.913B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $77.821B 31.64
Chugai Pharmaceutical (CHGCY) Japan $51.488B 23.01
Takeda Pharmaceutical (TAK) Japan $41.459B 8.40
Merck (MKGAF) Germany $24.092B 23.36
Astellas Pharma (ALPMY) Japan $17.210B 27.17
Sandoz Group AG (SDZNY) Switzerland $15.410B 0.00
Neurocrine Biosciences (NBIX) United States $13.631B 37.31
United Therapeutics (UTHR) United States $12.777B 13.62
Shionogi (SGIOY) Japan $11.322B 9.84
Catalent (CTLT) United States $10.041B 0.00
Cerevel Therapeutics Holdings (CERE) United States $7.567B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.118B 7.82
Revolution Medicines (RVMD) United States $6.372B 0.00
Orion OYJ (ORINY) Finland $6.014B 25.36
Ionis Pharmaceuticals (IONS) United States $5.933B 0.00
Madrigal Pharmaceuticals (MDGL) United States $5.916B 0.00
Summit Therapeutics (SMMT) United States $5.890B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.561B 0.00
Crinetics Pharmaceuticals (CRNX) United States $3.575B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $3.209B 0.00
Corcept Therapeutics (CORT) United States $3.016B 27.33
Dyne Therapeutics (DYN) United States $2.890B 0.00
PTC Therapeutics (PTCT) United States $2.747B 0.00
Indivior (INDV) United States $2.279B 10.80
Recursion Pharmaceuticals (RXRX) United States $2.201B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.127B 12.09
Catalyst Pharmaceuticals (CPRX) United States $1.779B 17.31
NewAmsterdam Pharma (NAMS) Netherlands $1.727B 0.00
Evotec AG (EVO) Germany $1.612B 0.00
Taro Pharmaceutical Industries (TARO) Israel $1.606B 24.14
Avadel Pharmaceuticals (AVDL) Ireland $1.520B 0.00
Ardelyx (ARDX) United States $1.478B 0.00
Soleno Therapeutics (SLNO) United States $1.417B 0.00
Pacira BioSciences (PCRX) United States $1.309B 12.45
BioCryst Pharmaceuticals (BCRX) United States $1.273B 0.00
Xencor (XNCR) United States $1.269B 0.00
4D Molecular Therapeutics (FDMT) United States $1.222B 0.00
Calliditas Therapeutics AB (CALT) Sweden $1.155B 0.00
Collegium Pharmaceutical (COLL) United States $1.039B 6.22
Centessa Pharmaceuticals (CNTA) United Kingdom $1.023B 0.00
Enliven Therapeutics (ELVN) United States $1.021B 0.00
Relay Therapeutics (RLAY) United States $0.970B 0.00
Cassava Sciences (SAVA) United States $0.946B 0.00
Cronos Group (CRON) Canada $0.909B 0.00
Ocular Therapeutix (OCUL) United States $0.891B 0.00
USANA Health Sciences (USNA) United States $0.857B 14.01
ARS Pharmaceuticals (SPRY) United States $0.839B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.806B 0.00
Sage Therapeutics (SAGE) United States $0.722B 0.00
Harrow (HROW) United States $0.636B 0.00
ProKidney (PROK) United States $0.626B 0.00
Exscientia (EXAI) United Kingdom $0.608B 0.00
Lyell Immunopharma (LYEL) United States $0.602B 0.00
Larimar Therapeutics (LRMR) United States $0.599B 0.00
Silence Therapeutics (SLN) United Kingdom $0.578B 0.00
Lexeo Therapeutics (LXEO) United States $0.573B 0.00
Esperion Therapeutics (ESPR) United States $0.566B 0.00
Savara (SVRA) United States $0.564B 0.00
Heron Therapeutics (HRTX) United States $0.542B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.535B 0.00
KalVista Pharmaceuticals (KALV) United States $0.509B 0.00
Bioventus (BVS) United States $0.505B 19.33
OmniAb (OABI) United States $0.496B 0.00
Siga Technologies (SIGA) United States $0.474B 6.06
Verve Therapeutics (VERV) United States $0.455B 0.00
Tourmaline Bio (TRML) United States $0.435B 0.00
Altimmune (ALT) United States $0.433B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.412B 0.00
Korro Bio (KRRO) United States $0.386B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.344B 0.00
Black Diamond Therapeutics (BDTX) United States $0.336B 0.00
Organogenesis (ORGO) United States $0.331B 62.38
Xeris Biopharma Holdings (XERS) United States $0.326B 0.00
Nature's Sunshine Products (NATR) United States $0.282B 17.91
Enanta Pharmaceuticals (ENTA) United States $0.272B 0.00
Fractyl Health (GUTS) United States $0.270B 0.00
Eliem Therapeutics (ELYM) United States $0.262B 0.00
Century Therapeutics (IPSC) United States $0.259B 0.00
Aquestive Therapeutics (AQST) United States $0.245B 0.00
ESSA Pharma (EPIX) Canada $0.238B 0.00
Akebia Therapeutics (AKBA) United States $0.224B 0.00
Acrivon Therapeutics (ACRV) United States $0.224B 0.00
Foghorn Therapeutics (FHTX) United States $0.224B 0.00
Pyxis Oncology (PYXS) United States $0.223B 0.00
Aldeyra Therapeutics (ALDX) United States $0.222B 0.00
Nanobiotix S.A (NBTX) France $0.217B 0.00
Avita Medical (RCEL) United States $0.216B 0.00
Nektar Therapeutics (NKTR) United States $0.215B 0.00
Prelude Therapeutics (PRLD) United States $0.214B 0.00
Incannex Healthcare (IXHL) Australia $0.211B 0.00
Metagenomi (MGX) United States $0.208B 0.00
Profound Medical (PROF) Canada $0.202B 0.00
Innate Pharma SA (IPHYF) France $0.200B 0.00
Zevra Therapeutics (ZVRA) United States $0.195B 0.00
Adherex Technologies (FENC) United States $0.185B 225.33
Elite Pharmaceuticals (ELTP) United States $0.180B 16.84
Achieve Life Sciences (ACHV) Canada $0.168B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.167B 0.00
Cardiol Therapeutics (CRDL) Canada $0.165B 0.00
Telomir Pharmaceuticals (TELO) United States $0.163B 0.00
Galectin Therapeutics (GALT) United States $0.163B 0.00
Regulus Therapeutics (RGLS) United States $0.158B 0.00
Context Therapeutics (CNTX) United States $0.147B 0.00
MediWound (MDWD) Israel $0.139B 0.00
CytoDyn (CYDY) United States $0.133B 0.00
Conduit Pharmaceuticals (CDT) United States $0.133B 0.00
OptiNose (OPTN) United States $0.131B 0.00
Karyopharm Therapeutics (KPTI) United States $0.119B 0.00
Citius Pharmaceuticals (CTXR) United States $0.113B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.112B 7.45
Journey Medical (DERM) United States $0.111B 0.00
FibroGen (FGEN) United States $0.111B 0.00
VAXART, INC (VXRT) United States $0.101B 0.00
Assertio Holdings (ASRT) United States $0.100B 4.57
Relmada Therapeutics (RLMD) United States $0.091B 0.00
Vivani Medical (VANI) United States $0.088B 0.00
AlloVir (ALVR) United States $0.088B 0.00
ProPhase Labs (PRPH) United States $0.088B 0.00
ARYA Sciences Acquisition Corp IV (ARYD) United States $0.086B 0.00
PMV Pharmaceuticals (PMVP) United States $0.086B 0.00
Aclaris Therapeutics (ACRS) United States $0.084B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.080B 0.00
SCYNEXIS (SCYX) United States $0.077B 1.09
Champions Oncology (CSBR) United States $0.068B 0.00
Tempest Therapeutics (TPST) United States $0.064B 0.00
Nutriband (NTRB) United States $0.059B 0.00
Reneo Pharmaceuticals (RPHM) United States $0.055B 0.00
Mural Oncology (MURA) Ireland $0.055B 0.00
BioLineRx (BLRX) Israel $0.053B 0.00
Protara Therapeutics (TARA) United States $0.053B 0.00
DURECT (DRRX) United States $0.051B 0.00
Lipocine (LPCN) United States $0.051B 0.00
Carisma Therapeutics (CARM) United States $0.047B 0.00
Inotiv (NOTV) United States $0.046B 0.00
CASI Pharmaceuticals (CASI) China $0.042B 0.00
Natural Alternatives (NAII) United States $0.041B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.041B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.037B 0.00
ElectroCore (ECOR) United States $0.037B 0.00
Surrozen (SRZN) United States $0.036B 0.00
Rafael Holdings (RFL) United States $0.035B 0.00
VYNE Therapeutics (VYNE) United States $0.033B 0.00
NRx Pharmaceuticals (NRXP) United States $0.032B 0.00
Enlivex Therapeutics (ENLV) Israel $0.030B 0.00
BioVie (BIVI) United States $0.028B 0.00
Viracta Therapeutics (VIRX) United States $0.026B 0.00
SHINECO (SISI) China $0.026B 0.00
Oncternal Therapeutics (ONCT) United States $0.026B 0.00
Unicycive Therapeutics (UNCY) United States $0.024B 0.00
Aptorum Group (APM) United Kingdom $0.023B 0.00
TherapeuticsMD (TXMD) United States $0.023B 0.00
Minerva Neurosciences (NERV) United States $0.023B 0.00
Gain Therapeutics (GANX) United States $0.022B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.021B 0.00
JanOne (JAN) United States $0.021B 0.00
Indaptus Therapeutics (INDP) United States $0.021B 0.00
PolyPid (PYPD) Israel $0.020B 0.00
Jaguar Animal Health (JAGX) United States $0.020B 0.00
MEI Pharma (MEIP) United States $0.019B 0.74
Iterum Therapeutics (ITRM) Ireland $0.019B 0.00
Nuvilex (PMCB) United States $0.018B 0.00
Talphera (TLPH) United States $0.018B 0.00
Lyra Therapeutics (LYRA) United States $0.018B 0.00
GlycoMimetics (GLYC) United States $0.017B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.016B 0.00
Traws Pharma (TRAW) United States $0.015B 0.00
Mannatech (MTEX) United States $0.015B 0.00
Alaunos Therapeutics (TCRT) United States $0.015B 0.00
Dominari Holdings (DOMH) United States $0.012B 0.00
Redhill Biopharma (RDHL) Israel $0.012B 0.00
Plus Therapeutics (PSTV) United States $0.011B 0.00
Avalo Therapeutics (AVTX) United States $0.011B 0.00
Cosmos Health (COSM) Greece $0.011B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.011B 0.00
Inhibikase Therapeutics (IKT) United States $0.010B 0.00
Biomerica (BMRA) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Molecular Templates (MTEM) United States $0.009B 0.00
Universe Pharmaceuticals INC (UPC) China $0.008B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Mangoceuticals (MGRX) United States $0.008B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.007B 0.00
Vivos Therapeutics (VVOS) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Ainos (AIMD) United States $0.006B 0.00
CERo Therapeutics Holdings (CERO) United States $0.006B 0.00
MyMD Pharmaceuticals (MYMD) United States $0.005B 0.00
Heatwurx (PCSA) United States $0.005B 0.00
Bio-Path Holdings (BPTH) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.002B 0.00
InMed Pharmaceuticals (INM) Canada $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.001B 0.00
PainReform (PRFX) Israel $0.001B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
China SXT Pharmaceuticals (SXTC) China $0.001B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Qilian Holding Group (QLI) China $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 5.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 30.12